Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial…

By P. Ridker, MR Stampfer, N. Rifai. Journal of the American Medical Association (JAMA), 2001

1,440 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. (2001, methodology): “pears to provide an improved method of determining global vascular risk.(13,28) Moreover, recent evidence from the Air”
Global vascular guidelines on the management of chronic limb-threatening ischemia (2019, background): “Strategies are urgently required to improve availability and affordability of drugs so that vascular specialists can treat their patients to target.321 There have been concerns that drugs reducing heart rate and blood pressure will worsen ischemia in patients with PAD.”
Epidemiology of peripheral artery disease. (2015, background): “Similarly, in the Framingham Study, a family history of IC significantly predicted incident IC.93 In a study of fraternal and identical twins, Carmelli et al94 estimated that 48% of the variability in ABI could be explained by additive genetic effects.”
Calorie restriction and aging: review of the literature and implications for studies in humans. (2003, background): “Thus, in addition to the well-recognized cardiovascular disease risk factors including lipids, lipoproteins (LDL and HDL cholesterol and triacylglycerol), and blood pressure, other factors, including hemostasis factors (eg, factor VII, fibrinogen, and plasminogen activator inhibitor type 1), C-react”